1. Introduction {#sec0005}
===============

Silver has been used for centuries as a biocidal material. In ancient time, silver was used to preserve water in the form of silver vessels or silver coins. Its medical use was documented as early as 750 AD. Starting from the seventeenth century, silver has been used as antiseptics in a number of medical situations such as cholera, eye infection, and burn wound [@bib0010]. The U.S. Food and Drug Administration (FDA) approved the use of charged silver solutions (*i.e.* electrocolloidals) as antibacterial agents in the 1920s. The application of silver was further expanded during the second half of the twentieth century as a disinfectant in conjunction with hydrogen peroxide.

Today, silver-containing products are used in a wide range of healthcare, food industry, and domiciliary applications and are commonly found in hard surface materials and textiles. In the food industry, silver-containing compounds or their mixtures are widely applied onto food-packaging materials, often in direct contact with the food. Such an extensive use of silver raises concerns about its safety, toxicity, and health risk. However, there is a paucity of information on the toxicity of silver. It is well known that ingesting large amount of silver preparations, which rarely happens, results in argyria, manifested by an irreversible gray to blue-black coloring of the skin due to subdermal silver deposit [@bib0055]. Also, the use of ionic silver and silver derivatives for treatment and prevention of infection of burn wounds or skin grafting has been associated with a number of side effects such as cytotoxicity, staining, methaemoglobinaemia and electrolyte disturbance, longer slough separation time, retardation of wound healing, and the possible inactivation of enzyme debriding agents [@bib0020]. The free silver ion (Ag^+^) is the most toxic species of silver. Toxicity testing in fathead minnow (*Pimephales promelas*) showed that free silver ion was about 15,000 and 300 times more acutely toxic than silver sulfide and silver chloride complexes, respectively, which are the major forms of silver in the environment [@bib0045]. However, the toxic effect of long-term exposure to low concentrations of silver has not been well studied.

There is a potential risk for the developing fetus when pregnant women are exposed to silver products. A case--control epidemiology study was conducted by [@bib0005] among women who delivered infants from 1977 to 1980 in a Massachusetts hospital. Trace element levels of public water were analyzed from the communities in which the women resided during pregnancy. The relationship between community drinking water quality and the occurrence of late adverse pregnancy outcomes was examined. After adjustment for confounding factors, the results suggested some association between maternal exposures to 0.001 mg/L of silver in the drinking water (1/100 of the EPA standard) and some increase in fetal developmental anomalies (ear, face, and neck). As the authors recognized, there are inferential limitations to epidemiologic studies and further research is needed to explore these findings.

The U.S. FDA evaluated data available on the use of silver mixtures as antimicrobial agents in food contact polymers and suspected that *in utero* exposure to silver may have an adverse effect on the immune system of the developing animal. A comprehensive study for risk assessment has been conducted in our group using a rat model and conventional toxicological and/or pathological endpoints to confirm that the previously observed adverse effects are due to silver ion alone, and to define the no observed effect level (NOEL) at or below which the adverse effect does not occur [@bib0080].

Microarray technology has become a powerful tool to explore the expression levels of thousands of genes or even complete genomes after exposure to toxicants and has thus found wide applications in toxicological research [@bib0075]. Toxicogenomics, defined as the "global analysis of gene expression in target cells or tissues in response to a toxicant," has emerged as a promising approach to evaluate mechanisms of action in toxicological models [@bib0025]. Information on the global gene expression profile may provide clues to understanding biological actions of toxic substances at the molecular, cellular, tissue, and individual animal levels. Tissue-specific gene expression profiles can provide a basis for understanding tissue function, enabling molecular characterization of differences between normal and diseased tissue. Toxicogenomics also provides opportunities for improvements in toxicity screening and risk assessment such as the development of new predictive models for identifying human health hazards and the identification of more precise molecular biomarkers of exposure [@bib0060]. In this application, toxicogenomic approaches usually are more sensitive than conventional toxicological endpoint assays and can assess toxic responses at low doses and at the very onset.

As a component of the comprehensive research [@bib0080], the current study used a toxicogenomic approach to study the effect of silver ions on the developing thymus at the transcriptional level by using whole-genome microarrays to study global gene expression changes in rat thymus of F1 generation offspring from dams exposed to different levels of silver ion. In the last years, some dozen reports appeared in the literature using toxicogenomics approach to study silver toxicity; however, the majority of these studies were on silver nanoparticles (AgNPs). Only a few evaluated silver ion toxicity either in a crustacean model [@bib0065], an *in vitro* fish model [@bib0100], or in bacteria [@bib0105]. Silver ions and AgNPs exerted toxicity through different mechanisms; the latter was affected by several other factors other than silver ion itself, including surface coating and particle size [@bib0065]. To our knowledge, this study represents the first evaluation of silver ion toxicity using toxicogenomics approach in a mammalian model.

2. Materials and methods {#sec0010}
========================

2.1. Experimental design {#sec0015}
------------------------

Thymus tissues were obtained from 5 male and 5 female F1 generation rat pups on postnatal day 26 in each treatment group that were randomly selected from the animals evaluated in [@bib0080]. In brief, 28-day-old male and female CD IGS VAF/+ rats were exposed *ad libidum* to Hydro-System water containing 0 (control), 0.4, 4.0, or 40.0 mg/kg body weight silver acetate for 10 weeks prior to mating and during the 2--3 week mating period. Sperm-positive females remained within their dose groups and were further exposed to silver acetate throughout the gestation and lactation periods. Pups were weaned on lactation day 21 and euthanized for tissue collection on day 26. To minimize potential litter effect, no more than one pup was randomly selected from each litter within a treatment group.

2.2. Tissue collection, RNA isolation, and quality assurance {#sec0020}
------------------------------------------------------------

Thymus from each pup was collected and snap-frozen in liquid N~2~ with 5 min after dissection. The samples were kept in a −80 °C freezer until processing for total RNA extraction. Thymus was disrupted using the TissueLyser (Qiagen, Valencia, CA) in the QIAzol Lysis Reagent (Qiagen) and total RNA was isolated on the EZ1 Advanced XL (Qiagen) automated RNA purification instrument using the EZ1 RNA Universal Tissue Kit (Qiagen) following the manufacturer\'s protocol, including an on-column DNase digestion. RNA concentration and purity (260/280 ratio) were measured with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Integrity of RNA samples was assessed by the Agilent 2100 Bioanalyzer (Santa Clara, CA) with the RNA 6000 Nano Reagent Kit from the same manufacturer.

2.3. Microarray experiment {#sec0025}
--------------------------

The total RNA samples were preprocessed for hybridization to GeneChip Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, CA) using the Affymetrix GeneChip 3′ IVT Express Kit following the manufacturer\'s protocol. In brief, 0.1 μg of total RNA was used to generate first-strand cDNA using reverse transcriptase and a T7-linked oligo(dT) primer. After second-strand synthesis, the double-stranded cDNA was then used for *in vitro* transcription with biotinylated UTP and CTP to amplify the product, referred to as cRNA amplification. Subsequent hybridization, wash, and staining were carried out using the Affymetrix GeneChip Hybridization, Wash, and Stain Kit and the manufacturer\'s protocols were followed. Briefly, biotinylated target cRNA was fragmented using heat and Mg^2+^ to sizes of 35--200 bp. Each fragmented cRNA target sample (approximately 12.5 μg) was individually hybridized to a GeneChip Rat Genome 230 2.0 Array at 45 °C for 16 h in Affymetrix GeneChip Hybridization Oven 645. After hybridization, the array chips were stained and washed using an Affymetrix Fluidics Station 450. The chips were then scanned on Affymetrix GeneChip Scanner 3000 7G and the image (.DAT) files were preprocessed using the Affymetrix GeneChip Command Console (AGCC) software v.3.2 to generate cell intensity (.CEL) files. The Rat Genome 230 2.0 Array comprises of over 31,000 probe sets representing approximately 28,700 well-substantiated rat genes. Prior to data analysis, all arrays referred to in this study were assessed for data quality using the Affymetrix Expression Console software v.1.2 and all quality assessment metrics (including spike-in controls during target preparation and hybridization) were found within boundaries.

2.4. Data processing and statistical analysis {#sec0030}
---------------------------------------------

Data analysis was carried out primarily using the U.S. FDA\'s ArrayTrack software system [@bib0085], [@bib0090]. The values of individual probes belonging to one probe set in .CEL files were summarized using the robust multi-array average (RMA) algorithm [@bib0040] embedded in ArrayTrack, which comprises of convolution background correction, quantile normalization, and median polish summarization. Normalized data for all samples were then analyzed by unsupervised principal component analysis (PCA) [@bib0070] and hierarchical cluster analysis (HCA) [@bib0015], both embedded in ArrayTrack, to identify patterns in the dataset and highlight similarities and differences among the samples. Subsequently, differentially expressed genes were selected using one-way analysis of variance (ANOVA) based on Welch\'s *t*-test. To improve moderated *t*-statistics, a gene-filtering procedure, namely I/NI-calls [@bib0030], was applied before the Welch\'s *t*-test to exclude non-informative genes. For each comparison between two experimental groups, the fold change (FC) of every annotated gene, together with their corresponding *p*-value, was used for selection of differentially expressed genes with cutoffs of *p* \< 0.05 and FC \> 1.5.

3. Results {#sec0035}
==========

3.1. Thymus and body weights {#sec0040}
----------------------------

[Table 1](#tbl0005){ref-type="table"} summarizes the effects of silver acetate on rat thymus and body weights in the subset of F1 generation pups used in this study (the full animal dataset was previously reported by [@bib0080]). Despite some decreases in the mean thymus and body weights in the higher dosing groups (4.0 and 40.0 mg/kg) compared with the control animals, thymus/body weight ratios were similar in all groups. No statistically significant effects were seen in any group.Table 1Summary of thymus and body weights and their ratios.Thymus Weight (mg)[a](#tblfn0005){ref-type="table-fn"}Body Weight (g)Thymus/Body Ratio (mg/g)Group 1 (Control)Male (5)[b](#tblfn0010){ref-type="table-fn"}302.9 ± 50.386.3 ± 4.83.5 ± 0.5Female (5)332.5 ± 14.381.5 ± 3.34.1 ± 0.3All (10)317.7 ± 38.283.9 ± 4.63.8 ± 0.5Group 2 (0.4 mg/kg)Male (5)307.1 ± 62.286.7 ± 7.23.5 ± 0.6Female (5)343.9 ± 95.781.3 ± 12.14.2 ± 0.7All (10)325.5 ± 78.584.0 ± 9.83.9 ± 0.7  Group 3 (4.0 mg/kg)Male (5)304.9 ± 45.478.2 ± 4.2[\*](#tblfn0015){ref-type="table-fn"}3.9 ± 0.7Female (5)280.5 ± 29.6[\*\*](#tblfn0020){ref-type="table-fn"}74.1 ± 5.2[\*](#tblfn0015){ref-type="table-fn"}3.8 ± 0.4All (10)292.7 ± 38.376.1 ± 5.0[\*\*](#tblfn0020){ref-type="table-fn"}3.9 ± 0.5  Group 4 (40.0 mg/kg)Male (5)273.1 ± 54.876.7 ± 7.9[\*](#tblfn0015){ref-type="table-fn"}3.5 ± 0.4Female (5)262.4 ± 58.6[\*](#tblfn0015){ref-type="table-fn"}71.2 ± 8.2[\*](#tblfn0015){ref-type="table-fn"}3.7 ± 0.7All (10)267.7 ± 53.8[\*](#tblfn0015){ref-type="table-fn"}74.0 ± 8.1[\*\*](#tblfn0020){ref-type="table-fn"}3.6 ± 0.6[^1][^2][^3][^4]

3.2. Global gene expression profiling {#sec0045}
-------------------------------------

Unsupervised data exploration by principal components analysis (PCA) was first conducted to identify major effects influencing the expression values in the experiment and to cluster samples based on their similarities or dissimilarities in global gene expression level. As shown in [Fig. 1](#fig0005){ref-type="fig"}, overall the samples were separated by gender into two major clusters. With each gender cluster, samples of different treatment groups were mixed with no discrete boundaries between different groups, suggesting treatment by silver acetate had little effect on global gene expression level. Results of hierarchical cluster analysis (HCA) ([Fig. 2](#fig0010){ref-type="fig"}) are consistent with the PCA results. The samples were clustered by gender into two major branches; within each gender cluster, however, the samples were not clustered into different treatment groups. Instead, the samples formed branches with no apparent relationships.Fig. 1Principal component analysis based on all probe sets in the array to cluster samples based on their similarities or dissimilarities in global gene expression level. The shape of each sample represents gender with male samples as cubes and females as balls. The color represents different treatment groups: grey, group 1 (control); green, group 2 (0.4 mg/kg); blue, group 3 (4.0 mg/kg); red, group 4 (40.0 mg/kg). The three axes PC1, PC2, and PC3 represent the first three principal components identified by the analysis. The percentage contribution of each component to the overall source of variation is included in the parentheses following each component name. The first principal component (PC1), which separates the samples into two gender clusters, has the largest variance (13.328), followed by PC2 (10.144) and PC3 (4.839).Fig. 2Hierarchical cluster analysis based on all probe sets in the array to cluster samples based on their similarities or dissimilarities in global gene expression level. The clustering was performed through Ward\'s minimum variance linkage on normalized expression data which are in log~2~ scale and color coded as shown in the scheme at the upper right corner. The tree on the right of the image shows clusters of genes (names not shown), while the tree on the top of the image shows clusters of samples. The naming of the samples follows "group name-gender-replicate"; for example, "G2-F-4" refers to the fourth female pup in group 2. The branches in a tree contain similar samples or genes.

3.3. Differential gene expression in treatment groups {#sec0050}
-----------------------------------------------------

Differences in gene expression between the treatment groups and the control were assessed using one-way analysis of variance (ANOVA). Since each gender had a distinct pattern in global gene expression ([Fig. 1](#fig0005){ref-type="fig"}, [Fig. 2](#fig0010){ref-type="fig"}), the analysis was conducted either separately for female and male animals, or with all animals in the same dose group.

Consistent with the results from PCA and HCA ([Fig. 1](#fig0005){ref-type="fig"}, [Fig. 2](#fig0010){ref-type="fig"}), one-way ANOVA using Welch\'s *t*-test also indicated treatment by silver acetate had little effect on gene expression. Using a stringent criterion of Bonferroni-adjusted *p* \< 0.05, the analysis revealed no differentially expressed genes (DEGs) from all treatment groups (vs. controls), whether the analysis was conducted within each gender group or with both gender groups combined. When a less stringent criterion (*p*-value not adjusted for multiple testing, i.e., unadjusted *p* \< 0.05) was used for the selection of DEGs, a number of significant genes with fold change (FC) \>1.5 were identified in each dose group ([Table 2](#tbl0010){ref-type="table"}, [Table 3](#tbl0015){ref-type="table"}, [Table 4](#tbl0020){ref-type="table"}). Treatment with 0.4 mg/kg of silver acetate resulted in 16, 16, and 15 DEGs for female, male, and combined groups. At 4.0 mg/kg, the numbers of DEGs were 13, 9, and 9 respectively; and at 40.0 mg/kg, the numbers were 14, 12, and 10.Table 2Differentially expressed genes in the groups treated with 0.4 mg/kg of silver.[a](#tblfn0025){ref-type="table-fn"}Gene IDGeneBank Acc. \#Gene nameDescriptionFC[b](#tblfn0030){ref-type="table-fn"}*p*FDR[c](#tblfn0035){ref-type="table-fn"}Female (16)1369113_atNM_019282Grem1Gremlin 10.670.0360.6091374474_atBE099085Cpne8Copine VIII (predicted)0.590.0080.5721378518_atBF394458Ewsr1Regulated endocrine-specific protein 180.530.0100.5721379547_atAA9646520.270.0140.5901380559_atAI030465Zic family member 2 (odd-paired homolog, Drosophila) (predicted)2.730.0000.4151381670_atBF4126811.820.0470.6381385098_atAW526343Sortilin-related VPS10 domain containing receptor 3 (predicted)0.630.0080.5711388985_atAI012869LOC100361467Cofilin 2, muscle (predicted)0.630.0240.6071389649_atAI4118970.660.0090.5721391830_atAI059204Cpne8Copine VIII (predicted)0.590.0060.5631395221_atAA892908Snx13Sorting nexin 13 (predicted)0.660.0430.6261395888_atBF5594981.610.0230.6071396019_atBF419464Coiled-coil-helix-coiled-coil-helix domain containing 5 (predicted)1.610.0360.6091396931_atAI1370911.680.0420.6221397064_atBE1144561.560.0340.6091397730_atC06959RGD1307235Similar to RIKEN cDNA 2310035C23 (predicted)0.650.0010.560  Male (16)1368487_atNM_021696Serpinb2Serine (or cysteine) peptidase inhibitor, clade B, member 21.560.0340.3761370382_atBI279526RT1-Db1RT1 class II, locus Db12.200.0140.3511375562_atBF408460Similar to \[Mouse primary response gene B94 mRNA, 3end.\], gene product0.660.0030.3061375758_atBF4049350.480.0480.3971376780_atAI172311Fam103a1Family with sequence similarity 103, member A10.390.0250.3641379435_atAI599463DguokDeoxyguanosine kinase (predicted)4.510.0220.3541385240_atAW523099Wdr33WD repeat domain 33 (predicted)0.640.0460.3951388236_x\_atM24026RT1-CE12RT1 class I, CE120.630.0480.3971388272_atAI411947LOC100363606Immunoglobulin heavy chain 1a (serum IgG2a)2.180.0340.3751391544_atBI285941Similar to adiponutrin0.550.0470.3961392118_atBE0998450.660.0060.3311392854_atBE116127RGD1564560Similar to RCK (predicted)1.750.0110.3491392894_atAI716194Fgl2Fibrinogen-like 21.700.0090.3491393795_atBG377397Zeb2Zinc finger E-box binding homeobox 20.610.0320.3721397064_atBE1144561.650.0030.3061398533_atBE105837Cyfip2Cytoplasmic FMR1 interacting protein 2 (predicted)0.580.0120.351  All (15)1367739_atNM_012786Cox8bcytochrome c oxidase, subunit 8B0.610.0440.9241371363_atBI277042Gpd1Glycerol-3-phosphate dehydrogenase 1 (soluble)0.550.0390.9241371400_atAI169092ThrspThyroid hormone responsive protein0.550.0450.9241375758_atBF4049350.610.0160.9241378518_atBF394458Ewsr1Regulated endocrine-specific protein 180.660.0080.9241379547_atAA9646520.370.0050.9241381670_atBF4126811.660.0170.9241382849_atAA8931954.150.0080.9241385380_atAI0449830.650.0090.9241386911_atNM_012505Atp1a2ATPase, Na+/K+ transporting, alpha 2 polypeptide0.600.0300.9241388272_atAI411947LOC100363606Immunoglobulin heavy chain 1a (serum IgG2a)1.780.0120.9241391544_atBI285941Similar to adiponutrin0.630.0130.9241393738_s\_atAI136864Mfhas1Malignant fibrous histiocytoma amplified sequence 1 (predicted)0.660.0390.9241393795_atBG377397Zeb2Zinc finger E-box binding homeobox 20.670.0030.9241397064_atBE1144561.600.0000.924[^5][^6][^7]Table 3Differentially expressed genes in the groups treated with 4.0 mg/kg of silver.[a](#tblfn0040){ref-type="table-fn"}Gene IDGeneBank Acc. \#Gene nameDescriptionFC[b](#tblfn0045){ref-type="table-fn"}*p*FDR[c](#tblfn0050){ref-type="table-fn"}Female (13)1368337_atNM_012794Glycam1Glycosylation-dependent cell adhesion molecule 10.500.0120.9861369342_atNM_052803Atp7aATPase, Cu^2+^ transporting, alpha polypeptide2.840.0100.9861372264_atBI277460Pck1Phosphoenolpyruvate carboxykinase 1, cytosolic0.400.0250.9861381208_atBE104595Hist3h2aHistone cluster 3, H2a1.510.0300.9861381990_atAA963979UDP-*N*-acetyl-alpha-[d]{.smallcaps}-galactosamine:polypeptide *N*-acetylgalactosaminyltransferase 10.660.0060.9861382849_atAA8931954.120.0490.9861383242_a\_atBF5612220.560.0220.9861384372_atBF545278Neural precursor cell-expressed, developmentally down-regulated gene 4A1.520.0480.9861388985_atAI012869LOC100361467Cofilin 2, muscle (predicted)0.620.0120.9861392189_atBE105136Rfx4Regulatory factor X, 4 (influences HLA class II expression)2.080.0260.9861393795_atBG377397Zeb2Zinc finger E-box binding homeobox 20.440.0220.9861397463_atBE105818Rab14RAB14, member RAS oncogene family0.640.0300.9861397730_atC06959RGD1307235Similar to RIKEN cDNA 2310035C23 (predicted)0.560.0010.986  Male (9)1372927_atAA891839Mrpl50Mitochondrial ribosomal protein L50 (predicted)0.620.0010.9941380773_atBI2887676-Phosphogluconolactonase (predicted)1.520.0140.9941381858_atBM387283Trim14Tripartite motif protein 14 (predicted)0.670.0130.9941384136_atBI291045Osbpl3Oxysterol binding protein-like 30.660.0440.9941385635_atAI029143Cd5lCD5 antigen-like2.170.0220.9941392012_atBE100353LOC6865670.610.0430.9941392894_atAI716194Fgl2Fibrinogen-like 21.520.0450.9941393738_s\_atAI136864Mfhas1Malignant fibrous histiocytoma-amplified sequence 1 (predicted)0.530.0330.9941393795_atBG377397Zeb2Zinc finger E-box binding homeobox 20.460.0380.994  All (9)1369342_atNM_052803Atp7aATPase, Cu^2+^ transporting, alpha polypeptide1.970.0350.9091370312_atM88469Spon1Spondin 10.650.0380.9091379547_atAA9646520.460.0280.9091382849_atAA8931953.100.0230.9091383242_a\_atBF5612220.660.0210.9091385635_atAI029143Cd5lCD5 antigen-like1.740.0210.9091392012_atBE100353LOC6865670.650.0090.9091392189_atBE105136Rfx4Regulatory factor X, 4 (influences HLA class II expression)1.820.0200.9091393795_atBG377397Zeb2Zinc finger E-box binding homeobox 20.450.0010.896[^8][^9][^10]Table 4Differentially expressed genes in the groups treated with 40.0 mg/kg of silver.[a](#tblfn0055){ref-type="table-fn"}Gene IDGeneBank Acc. \#Gene nameDescriptionFC[b](#tblfn0060){ref-type="table-fn"}*p*FDR[c](#tblfn0065){ref-type="table-fn"}Female (14)1368826_atNM_012531ComtCatechol-*O*-methyltransferase0.320.0300.9981369342_atNM_052803Atp7aATPase, Cu^2+^ transporting, alpha polypeptide2.130.0210.9981378346_atAI385237Similar to IQ motif and WD repeats 10.620.0210.9981379170_atBF3930590.660.0120.9981381613_atBI2902130.390.0200.9981382597_atBF288069Formin binding protein 3 (predicted)0.630.0010.9981383187_a\_atAA944136Bol, boule-like (Drosophila) (predicted)0.590.0300.9981383242_a\_atBF5612220.500.0160.9981383598_atAI136294Wdr91WD repeat domain 911.550.0130.9981384067_atBF2883610.400.0240.9981384126_a\_atAW917217Cytoskeleton-associated protein 2 (predicted)0.600.0040.9981384136_atBI291045Osbpl3Oxysterol binding protein-like 31.900.0110.9981388985_atAI012869LOC100361467Cofilin 2, muscle (predicted)0.530.0270.9981392591_atAI170983MGC125002Similar to RIKEN cDNA 5830433M190.650.0020.998  Male (12)1368487_at[\*](#tblfn0070){ref-type="table-fn"}NM_021696Serpinb2Serine/cysteine peptidase inhibitor, clade B, member 21.640.0020.0731370371_a\_atU23056Ceacam1///Ceacam10CEA-related cell adhesion molecule 100.450.0140.1301372725_atAI411594Plscr2Phospholipid scramblase 21.570.0470.2081378738_atBE097574Kcnab1Potassium voltage-gated channel, shaker-related subfamily, beta member 11.670.0490.2131378866_at[\*](#tblfn0070){ref-type="table-fn"}BF401176Actin-binding LIM protein 11.850.0030.0791381839_atAA957129Similar to hypothetical protein FLJ13855 (predicted)0.600.0270.1611383163_atAA817898IgjImmunoglobulin joining chain1.520.0390.1911392854_at[\*](#tblfn0070){ref-type="table-fn"}BE116127RGD1564560Similar to RCK (predicted)2.020.0060.0941393738_s\_atAI136864Mfhas1Malignant fibrous histiocytoma amplified sequence 1 (predicted)0.540.0310.1741394585_at[\*](#tblfn0070){ref-type="table-fn"}BE116089Adenosine deaminase, RNA-specific0.550.0000.0521397212_at[\*](#tblfn0070){ref-type="table-fn"}AW534279Spermatid perinuclear RNA binding protein0.640.0010.0641397463_atBE105818Rab14RAB14, member RAS oncogene family0.500.0170.1401397635_at[\*](#tblfn0070){ref-type="table-fn"}BM390325Serpinb3aSerine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 3A1.830.0040.080  All (10)1369342_atNM_052803Atp7aATPase, Cu^2+^ transporting, alpha polypeptide2.220.0070.2281370371_a\_atU23056Ceacam1///Ceacam10CEA-related cell adhesion molecule 100.490.0020.1621381613_atBI2902130.500.0050.2041383242_a\_atBF5612220.600.0220.2881384067_atBF2883610.480.0050.2041384393_atBE120370Cln3p1.630.0340.3211388985_atAI012869LOC100361467Cofilin 2, muscle (predicted)0.610.0050.2041393795_atBG377397Zeb2Zinc finger E-box binding homeobox 20.610.0120.2561394671_atAI454769Glucosamine (*N*-acetyl)-6-sulfatase (predicted)0.600.0140.2631397463_atBE105818Rab14RAB14, member RAS oncogene family0.610.0030.171[^11][^12][^13][^14]

Although the numbers of DEGs did not show dose dependency, the false discovery rate (FDR), which is a statistic (*p*-value) moderately adjusted for multiple testing, were markedly different among different dose groups, and in some cases between different gender groups with the same dose group as well. Remarkably, six probe sets in the male group of the highest dose group (40.0 mg/kg) had an FDR \< 0.1 (highlighted in [Table 4](#tbl0020){ref-type="table"}). Among these probe sets, two are serine/cysteine peptidase inhibitor, namely Serpinb2 and Serpinb3a, one is predicted to be similar to the regulator of K^+^ conductance (RCK), another one is an RNA-specific adenosine deaminase and the remaining two are actin binding protein and RNA binding protein, respectively. The heat map shown in [Fig. 3](#fig0015){ref-type="fig"} illustrates the differential expression of these genes in the high-dose group (40.0 mg/kg) compared with the control group.Fig. 3Heat map showing the differential expression of some genes with FDR \< 0.1 in males of the high dose group (40.0 mg/kg, G4) compared with the control group (G1). The data are normalized signal intensity value in log~2~ scale and color coded as shown in the scheme at the upper right corner. The naming of the samples follows "group name-gender-replicate"; for example, "G4-M-1" refers to the first male pup in group 4.

The numbers of DEGs for each treatment or gender group as well as the numbers of overlapping genes are plotted in the Venn diagrams shown in [Fig. 4](#fig0020){ref-type="fig"}. Within the same dose group ([Fig. 4](#fig0020){ref-type="fig"}A), it is apparent that different gender groups shared no or very small numbers of genes compared to the total number of changed genes in each gender group, suggesting the gene expression changes were gender-dependent. Similarly, different dose groups within the same gender group also had very few overlapped genes compared to the total number of changed genes in each dose group ([Fig. 4](#fig0020){ref-type="fig"}B), suggesting the gene expression changes were also dose-dependent. However, source of variance (SV) plot from two-way ANOVA on dose and gender ([Fig. 5](#fig0025){ref-type="fig"}) indicated that gender had a much greater contribution than dose to the gene expression changes.Fig. 4Venn diagrams showing overlap of differentially expressed genes (DEGs) between different gender groups in the same dose group (A) and between different dose groups in the same gender group (B). The total number of DEGs in each group is included in the parentheses under the group name.Fig. 5Source of variance (SV) plot from two-way ANOVAs showing the contribution from gender, dose, their interaction (gender × dose), and error.

4. Discussion {#sec0055}
=============

With the increasing application of silver-containing compounds as antimicrobial agents in the food industry, it is imperative to study their safety, toxicity, and health effect. The U.S. FDA evaluated data available on the use of silver mixtures as antimicrobial agents in food contact polymers and suspected that *in utero* exposure to silver may have an adverse effect on the immune system of the developing animal. A comprehensive study for risk assessment has been conducted in our group using a rat model and conventional toxicological and/or pathological endpoints to confirm that the previously observed adverse effects are due to silver ion alone and to define the NOEL [@bib0080].

As a component of the comprehensive research, the present study used a toxicogenomic approach to study the effect of silver ions on the developing thymus at the transcriptional level. Global gene expression profile in rat thymus of F1 generation pups at postnatal day 26 following maternal exposure to silver acetate at 0, 0.4, 4.0, or 40.0 mg/kg in drinking water are reported here. Unsupervised data exploration by PCA ([Fig. 1](#fig0005){ref-type="fig"}) and HCA ([Fig. 2](#fig0010){ref-type="fig"}) revealed that the samples were separated by gender into two major clusters. Within each gender group, however, no distinct expression patterns were identified for different dose groups, suggesting treatment by silver acetate had little effect on global gene expression. Consistently, one-way ANOVA identified only about a dozen DEGs in each dose group with FC \> 1.5 and unadjusted *p* \< 0.05, and none of these genes had an FDR \<0.05 ([Table 2](#tbl0010){ref-type="table"}, [Table 3](#tbl0015){ref-type="table"}, [Table 4](#tbl0020){ref-type="table"}). Six genes had an FDR \< 0.1 in the males of the highest treatment group ([Table 4](#tbl0020){ref-type="table"}); however, visual inspection of the heat map suggests these genes are likely false-positives ([Fig. 4](#fig0020){ref-type="fig"}). Taken together, these results indicate silver acetate up to 40.0 mg/kg did not affect gene expression in the developing thymus.

In the large-scale study, no histopathological abnormalities in thymus were identified in the F1 generation pups in any of the dosing groups [@bib0080]. Combined with the observation that thymus-to-body-weight ratios were not affected ([Table 1](#tbl0005){ref-type="table"}), the current study suggests that *in utero* exposure to silver ions up to 26.0 mg/kg (equivalent to 40.0 mg/kg silver acetate) did not have an adverse effect on the developing thymus.

A parallel component study [@bib0095] on natural killer (NK) activity and mitogen-induced lymphocyte proliferation in the spleen of the F1 generation pups has found that maternal exposure to 4.0 and 40.0 mg/kg silver acetate resulted in reduced T-cell development and cell-mediated immune functions in 4-day pups, and reduced TCR+ cells and cell-mediated immune functions in 26-day-old pups, although exposure to low concentration of silver acetate (0.4 mg/kg) has slight beneficial effect on NK activity in 26-day pups. In contrast, no effect was observed on thymic lymphocytes. Hultman et al. [@bib0035] found that Brown Norway (BN) rats exposed to silver in dental amalgam restorations had significantly increased metal (including silver) concentrations in tissue in the order kidney \> spleen \> cerebrum occipital lobe \> cerebellum \> liver \> thymus. For example, mercury concentration in spleen is more than 30-fold higher than that in thymus. Silver accumulation may follow the same pattern as mercury. This may partly explain the results of [@bib0095] that silver acetate had a significant impact on the splenic but not thymic immune system and may also help to explain the findings of the current study that silver acetate had not significant effect on thymic gene expression.

It should be noted that silver ions may exert systemic effects on the developing pups that are not evident in specific organs. McIntyre et al. [@bib0050] reported that a 12-month infant overdosed with colloidal silver in the form of dietary supplements manifested global developmental retardation, although this case was complicated by malnutrition. In the comprehensive study [@bib0080], higher runt numbers and low average body weights were observed in pups following maternal exposure to silver acetate at high concentrations (4.0 and 40.0 mg/kg). In addition, prenatal death rate of newborns was also higher in dams exposed to high concentrations (4.0 and 40.0 mg/kg) of silver acetate.

5. Conclusions {#sec0060}
==============

In the present study, we used a toxicogenomic approach to study the effect of silver ions on the developing thymus by measuring transcriptome changes in rat thymus of F1 generation pups following maternal exposure to silver acetate. Gene expression profiling analyses indicate that silver acetate up to 40.0 mg/kg did not affect gene expression in the developing thymus. Combined with the observation that thymus-to-body-weight ratios were not affected, and no histopathological abnormalities in thymus were identified in the pups, the current study suggests that *in utero* exposure to silver ions up to 26.0 mg/kg (equivalent to 40.0 mg/kg silver acetate) did not have an adverse effect on the developing thymus.
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==============================
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[^1]: Thymus was weighed after frozen in liquid nitrogen.

[^2]: The number in parentheses indicates the number of animals in each dose and sex group.

[^3]: Significant at *p* \< 0.05.

[^4]: Significant at *p* \< 0.01.

[^5]: The analysis was conducted within each gender group ("Female" or "Male") or with both gender groups combined ("All"). The number of significant genes in each gender group is included in parentheses following the gender name.

[^6]: Fold changes relative to the control group.

[^7]: False discovery rate, which is the probability of having false tests among all the significant tests. For example, an FDR of 0.05 indicates that 5% of the significant genes may have been identified by chance (i.e., the false-positives).

[^8]: The analysis was conducted within each gender group ("Female" or "Male") or with both gender groups combined ("All"). The number of significant genes in each gender group is included in parentheses following the gender name.

[^9]: Fold changes relative to the control group.

[^10]: False discovery rate, which is the probability of having false tests among all the significant tests. For example, an FDR of 0.05 indicates that 5% of the significant genes may have been identified by chance (i.e., the false-positives).

[^11]: The analysis was conducted within each gender group ("Female" or "Male") or with both gender groups combined ("All"). The number of significant genes in each gender group is included in parentheses following the gender name.

[^12]: Fold changes relative to the control group.

[^13]: False discovery rate, which is the probability of having false tests among all the significant tests. For example, an FDR of 0.05 indicates that 5% of the significant genes may have been identified by chance (i.e., the false-positives).

[^14]: Genes with FDR \< 0.1.
